Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia

Tamer A Elbedewy,1 Mohamed A Elsebaey,1 Samah A Elshweikh,1 Heba Elashry,2 Sherief Abd-Elsalam2 1Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt Background and aims: Thrombocytopen...

Full description

Bibliographic Details
Main Authors: Elbedewy TA, Elsebaey MA, Elshweikh SA, Elashry H, Abd-Elsalam S
Format: Article
Language:English
Published: Dove Medical Press 2019-02-01
Series:Therapeutics and Clinical Risk Management
Subjects:
Online Access:https://www.dovepress.com/predictors-for-eltrombopag-response-in-patients-with-hepatitis-c-virus-peer-reviewed-article-TCRM
_version_ 1818718416256630784
author Elbedewy TA
Elsebaey MA
Elshweikh SA
Elashry H
Abd-Elsalam S
author_facet Elbedewy TA
Elsebaey MA
Elshweikh SA
Elashry H
Abd-Elsalam S
author_sort Elbedewy TA
collection DOAJ
description Tamer A Elbedewy,1 Mohamed A Elsebaey,1 Samah A Elshweikh,1 Heba Elashry,2 Sherief Abd-Elsalam2 1Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt Background and aims: Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is the first study aiming to determine the predictive factors of response to eltrombopag therapy in patients with HCV-associated thrombocytopenia. Patients and methods: This prospective study was carried out on 130 patients with chronic HCV-associated thrombocytopenia (<50,000×109/L) that precludes the initiation of HCV therapy. Eltrombopag was initiated at a dose of 25 mg once daily; the dose was adjusted with 25 mg increments every 2 weeks to achieve the target platelet count. The primary end point was to achieve stable target platelet count (50,000–100,000×109/L) required to initiate antiviral therapy. Results: Treatment response was achieved in 111 (85.38%) patients. This prospective study showed that megakaryocyte hypoplasia or aplasia and splenectomy were independent risk factors for eltrombopag nonresponse in chronic HCV-associated thrombocytopenic patients. Conclusion: Eltrombopag is safe and effective for patients with HCV-associated thrombocytopenia. Bone marrow examination should be considered before initiating treatment with eltrombopag in chronic HCV-associated thrombocytopenic patients, especially in patients with splenectomy. Keywords: HCV, therapy, thrombocytopenia, predictors, splenectomy, direct-acting antivirals, DAAs
first_indexed 2024-12-17T19:50:42Z
format Article
id doaj.art-053e15128f6a48b8aa54899dcad949c6
institution Directory Open Access Journal
issn 1178-203X
language English
last_indexed 2024-12-17T19:50:42Z
publishDate 2019-02-01
publisher Dove Medical Press
record_format Article
series Therapeutics and Clinical Risk Management
spelling doaj.art-053e15128f6a48b8aa54899dcad949c62022-12-21T21:34:43ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2019-02-01Volume 1526927444020Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopeniaElbedewy TAElsebaey MAElshweikh SAElashry HAbd-Elsalam STamer A Elbedewy,1 Mohamed A Elsebaey,1 Samah A Elshweikh,1 Heba Elashry,2 Sherief Abd-Elsalam2 1Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt Background and aims: Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is the first study aiming to determine the predictive factors of response to eltrombopag therapy in patients with HCV-associated thrombocytopenia. Patients and methods: This prospective study was carried out on 130 patients with chronic HCV-associated thrombocytopenia (<50,000×109/L) that precludes the initiation of HCV therapy. Eltrombopag was initiated at a dose of 25 mg once daily; the dose was adjusted with 25 mg increments every 2 weeks to achieve the target platelet count. The primary end point was to achieve stable target platelet count (50,000–100,000×109/L) required to initiate antiviral therapy. Results: Treatment response was achieved in 111 (85.38%) patients. This prospective study showed that megakaryocyte hypoplasia or aplasia and splenectomy were independent risk factors for eltrombopag nonresponse in chronic HCV-associated thrombocytopenic patients. Conclusion: Eltrombopag is safe and effective for patients with HCV-associated thrombocytopenia. Bone marrow examination should be considered before initiating treatment with eltrombopag in chronic HCV-associated thrombocytopenic patients, especially in patients with splenectomy. Keywords: HCV, therapy, thrombocytopenia, predictors, splenectomy, direct-acting antivirals, DAAshttps://www.dovepress.com/predictors-for-eltrombopag-response-in-patients-with-hepatitis-c-virus-peer-reviewed-article-TCRMThrombocytopeniaHCVeltrombobagpredictors
spellingShingle Elbedewy TA
Elsebaey MA
Elshweikh SA
Elashry H
Abd-Elsalam S
Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
Therapeutics and Clinical Risk Management
Thrombocytopenia
HCV
eltrombobag
predictors
title Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
title_full Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
title_fullStr Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
title_full_unstemmed Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
title_short Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
title_sort predictors for eltrombopag response in patients with hepatitis c virus associated thrombocytopenia
topic Thrombocytopenia
HCV
eltrombobag
predictors
url https://www.dovepress.com/predictors-for-eltrombopag-response-in-patients-with-hepatitis-c-virus-peer-reviewed-article-TCRM
work_keys_str_mv AT elbedewyta predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia
AT elsebaeyma predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia
AT elshweikhsa predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia
AT elashryh predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia
AT abdelsalams predictorsforeltrombopagresponseinpatientswithhepatitiscvirusassociatedthrombocytopenia